Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

BRANFORD, Conn., May 28, 2024 (Newswire.com) - RNAConnect, a pioneering life science tools company, officially announced the commercial launch of UltraMarathonRT™ (uMRT), a next-generation, ...

Jerold Chun, MD, PhD, is a professor in the Center for Neurologic Diseases at Sanford Burnham Prebys and the senior and corresponding author of the manuscript. Alzheimer’s disease is the most common ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for ...

BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced a landmark ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

ROME’s proprietary LINE-1 RT inhibitors demonstrated neuroprotective effect on dopaminergic neuron survival in both in vitro and in vivo neurotoxin models of Parkinson’s disease ROME’s LINE-1 RT ...

BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for ...

Inhibition of LINE-1 Reverse Transcriptase (RT) holds promise as the first non-immunosuppressant treatment approach for Type 1 interferon-driven diseases BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ROME ...